Interventions for Tuberculosis Control and Elimination 2002

1178. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines
against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further
studies that may elucidate the potential use of thiridazine as anti-tuberculosis
therapy. J Antimicrob Chemother 2001; 47: 505-11.
1179. Crowle AJ, Douvas GS, May MH. Chlorpromazine: a drug potentially useful
for treating mycobacterial infections. Chemotherapy 1992; 38: 410-9.
1180. Nagata A, Ando T, Izumi R, Sakakibara H, Take T, Hayano K, Abe J. Studies
on tuberactinomycin (tuberactin), a new antibiotic. I Taxonomy of producing
strain, isolation and characterization. J Antibiotics 1968; 21: 681-7.
1181. Toyohara M, Nagata A, Havano K, Abe J. Study of the antituberculous activity
of tuberactinomycin, a new antimicrobial drug.
100: 228-30.
Am Rev Respir Dis 1969;
1182. Ohsato T, Toyohara M. Clinical study on tuberactinomycin, a new antibiotic.
Kekkaku 1971; 46: 59-63.
1183. Ando T, Matsuura K, Izumi R, Noda T, Take T, Nagata A, Abe J. Studies on
tuberactinomycin. II isolation and properties of tuberactinomycin-N, a new
tuberactinomycin group antibiotic. J Antibiotics 1971; 24: 680-6.
1184. Toyohara M. An experimental study on the antituberculous activity of tuberactinomycin-N.
Kekkaku 1972; 47: 181-7.
1185. Orme I. Beyond BCG: the potential for a more effective TB vaccine. Mol
Med Today 1999; 5: 487-92.
1186. Young DB. Current tuberculosis vaccine development. Clin Infect Dis 2000;
30 (Suppl 3): S254-S256.
1187. Kaufmann SHE. Is the development of a new tuberculosis vaccine possible?
(Commentary). Nature Med 2000; 6: 955-60.
1188. Dreher D, Kok M, Pechère JC, Nicod LP. New strategies against an old plague:
genetically engineered tuberculosis vaccines.
130: 1925-9.
Schweiz Med Wochenschr 2000;
1189. Stanford JL. Immunotherapy for leprosy and tuberculosis. Progr Drug Research
1989; 33: 415-47.
1190. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae
in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled
trial. Lancet 1999; 354: 116-9.
1191. Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Hom DL,
Wallis RS, Hirsch CS, Wolski K, Foulds J, Mugerwa RD, Ellner JJ. Randomized
controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency
virus-infeted Ugandan adults with newly diagnosed tuberculosis.
Infect Dis 2000; 181: 1304-12.
J
1192. Mayo REP, Stanford JL. Double-blind placebo-controlled trial of Mycobacterium
vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.
Trans R Soc Trop Med Hyg 2000; 94: 563-8.
249